29th Sep 2021 14:39
MGC Pharmaceuticals Ltd - Australian biopharma company - Says distribution partner AMC Holdings Inc has placed an initial order for 1,000 units of CimetrA on an expedited basis in order to fast track the approval process for the medication to be distributed and sold in the US. The move follows supply & distribution agreement signed with AMC in August.
In addition, AMC is currently working with both the University of South Florida in Tampa, and the Holy Cross Hospital in Fort Lauderdale, to submit CimetrA, and shortly thereafter CogniCann, to their respective internal review boards for approval. The approval from these boards is the first step for both facilities to launch US based clinical trials for CimetrA and CogniCann.
Current stock price: 3.20 pence
Year-to-date change: up 34% since listing in February
By Evelina Grecenko; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
MXC.L